Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of (R)-Ramelteon. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A known ✓ | P48039 | 20/20 | 1.00 |
| ▸ | MTNR1B known ✓ | P49286 | 20/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 1.00 |
| ▸ | USP2 | O75604 | 1/20 | 1.00 |
| ▸ | NQO2 | P16083 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| (R)-Ramelteon SCHEMBL1566122 | 1.00 | MTNR1A (1.00) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| Ramelteon SCHEMBL29237 | 1.00 | MTNR1A (1.00) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| Ramelteon SCHEMBL29380213 | 1.00 | MTNR1A (1.00) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| (R)-Ramelteon SCHEMBL29827337 | 1.00 | MTNR1A (1.00) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| SCHEMBL1566589 | 0.91 | MTNR1A (1.00) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| SCHEMBL1567007 | 0.88 | MTNR1A (1.00) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| SCHEMBL1567415 | 0.88 | MTNR1A (1.00) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| SCHEMBL3065294 | 0.87 | MTNR1A (1.00) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| SCHEMBL13985044 | 0.86 | MTNR1A (0.76) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| SCHEMBL1612991 | 0.85 | MTNR1A (0.78) | MTNR1AMTNR1BABCB11SIGMAR1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 342 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10555919-B2 | Melatonin in autoimmune disease | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2020-02-11 | — | — | US | claimed |
| US-10098866-B2 | Pharmaceutical preparation containing copolyvidone | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-10-16 | — | — | US | claimed |
| US-20170333371-A1 | MELATONIN IN AUTOIMMUNE DISEASE | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2017-11-23 | — | — | US | claimed |
| US-20170128409-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR ATTENTION DEFICIT/HYPERACTIVITY DISORDER | TAKEDA PHARMACEUTICALS CO (JP) | 2017-05-11 | — | — | US | claimed |
| US-20170065553-A1 | ORALLY DISPERSIBLE TABLET | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-03-09 | — | — | US | claimed |
| US-20170020841-A1 | PHARMACEUTICAL PREPARATION CONTAINING COPOLYVIDONE | TAKEDA PHARMACEUTICALS CO (JP) | 2017-01-26 | — | — | US | claimed |
| US-8821926-B2 | Tablet containing hardly soluble active ingredient | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-09-02 | — | — | US | claimed |
| US-20140235709-A1 | ORALLY DISPERSIBLE TABLET | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-08-21 | — | — | US | claimed |
| US-20140235879-A1 | ORALLY DISPERSIBLE TABLET | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-08-21 | — | — | US | claimed |
| EP-2765985-A1 | ORALLY DISPERSIBLE TABLET | Takeda Pharmaceutical Company Limited (JP) | 2014-08-20 | — | — | EP | claimed |
| EP-1334732-A1 | PHARMACEUTICAL PREPARATION CONTAINING COPOLYVIDONE | Takeda Chemical Industries, Ltd. (JP) | 2003-08-13 | — | — | EP | claimed |
| EP-1214944-A1 | PERCUTANEOUS ABSORPTION AGENTS | Takeda Chemical Industries, Ltd. (JP) | 2002-06-19 | — | — | EP | claimed |
| EP-0885210-B1 | Tricylic compounds having binding affinity for melatonin receptors, their production and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2002-06-12 | — | — | EP | claimed |
| EP-1206943-A1 | MATRIX ADHERING TO NASAL MUCOSA | Takeda Chemical Industries, Ltd. (JP) | 2002-05-22 | — | — | EP | claimed |
| US-6348485-B1 | ramelteon and one of zolpidem, zopiclone, brotizolam and triazolam | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-02-19 | — | — | US | claimed |
| EP-1100508-A2 | PHARMACEUTICAL COMBINATION COMPRISING A TRICYCLIC COMPOUND AND AT LEAST ONE OF ZOLPIDEM, ZOPICLONE AND BROTIZOLAM FOR TREATING OR PREVENTING SLEEP DISORDERS | Takeda Chemical Industries, Ltd. (JP) | 2001-05-23 | — | — | EP | claimed |
| US-6034239-A | BINDIG TO MELATONIN RECEPTORS; SLEEP DISORDERS; GLANDULAR DISORDERS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-03-07 | — | — | US | claimed |
| WO-1999063977-A2 | PHARMACEUTICAL COMBINATION COMPRISING A TRICYCLIC COMPOUND AND AT LEAST ONE OF ZOLPIDEM, ZOPICLONE, TRIAZOLAM AND BROTIZOLAM FOR TREATING OR PREVENTING SLEEP DISORDERS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-12-16 | — | — | WO | claimed |
| EP-0885210-A1 | Tricylic compounds having binding affinity for melatonin receptors, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1998-12-23 | — | — | EP | claimed |
| WO-1997032871-A1 | TRICYCLIC COMPOUNDS, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-09-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170020841-A1 | PHARMACEUTICAL PREPARATION CONTAINING COPOLYVIDONE | PRCP, COPS6, COPS5 | MTNR1A 3487/4885MTNR1B 3104/4885ABCB11 108/4885 |
| US-10098866-B2 | Pharmaceutical preparation containing copolyvidone | PRCP, COPS6, COPS5 | MTNR1A 3487/4885MTNR1B 3104/4885ABCB11 108/4885 |
| US-20170128409-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR ATTENTION DEFICIT/HYPERACTIVITY DISORDER | AANAT, DBH, CHAT | MTNR1A 99/4885MTNR1B 56/4885ABCB11 1696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.